All In Biotech

Drug Trial Radar · NCT04263337

NFL LONG Prospective Study

Neurologic Function Across the Lifespan: A Prospective, LONGitudinal, and Translational Study for Former National Football League Players

Last checked: Nov 20, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Mar 12, 2020

Primary completion

Aug 2028

Study completion Aug 2028

Sponsor

Lead sponsor
University of North Carolina, Chapel HillAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Boston Children's Hospital; Medical College of Wisconsin; National Football League
First posted
Feb 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Male only, from 50 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this 5-year prospective research study is to characterize the association between concussions, sub-concussive exposure, and long-term neurologic health outcomes in former NFL players. To achieve the study aims, the investigators will conduct detailed research visits that include clinical outcome assessments, blood-based biomarkers, advanced magnetic resonance imaging (MRI), positron emission tomography (PET) using investigational tracers and genetic testing. Ultimately, the goal of this study is to translate the findings from this study into clinical, interventional studies for at risk former NFL players.

Conditions

  • Concussion, Brain

Interventions

  • [11C] PiBDrug

    Per study protocol static PET images will be acquired after IV infusion of CPiB to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.

  • [18F] PBR111Drug

    Per study protocol static PET images will be acquired after IV infusion of F-PBR111 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.

  • [18F] FlortaucipirDrug

    Per study protocol static PET images will be acquired after IV infusion of F-T807 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PET Neuroimaging SUVR Over TimeTime frame: Baseline, up to 3 Year Follow-up
  2. MRI Neuroimaging Over TimeTime frame: Baseline, up to 3 Year Follow-up
  3. Serum Biomarkers Over TimeTime frame: Baseline, up to 3 Year Follow-up
  4. Mean Change in Headache Impact Test (HIT-6)Time frame: Baseline, up to 3 Year Follow-up
  5. Mean Change in MDS-UPDRS ScoreTime frame: Baseline, up to 3 Year Follow-up
  6. Mean Change in Postural Stability-Sensory Organization TestTime frame: Baseline, up to 3 Year Follow-up
  7. Mean Change in Structured Inventory of Malingered Symptomatology (SIMS)Time frame: Baseline, up to 3 Year Follow-up
  8. Mean Change in Medical Symptom Validity Test (MSVT)Time frame: Baseline, up to 3 Year Follow-up
  9. Mean Change in National Institute of Health (NIH) ToolboxTime frame: Baseline, up to 3 Year Follow-up
  10. Mean Change in Rey Auditory Verbal Learning Test (RAVLT)Time frame: Baseline, up to 3 Year Follow-up
  11. Mean Change in Dot Counting TestTime frame: Baseline, up to 3 Year Follow-up
  12. Mean Change in Delis Kaplan Executive Function System (DKEFS) Verbal Fluency, Trailmaking Test (TMT), and Color-Word InterferenceTime frame: Baseline, up to 3 Year Follow-up
  13. Mean Change in Satisfaction with Life Scale (SWLS) ScoreTime frame: Baseline, up to 3 Year Follow-up
  14. Mean Change in Alcohol Use Disorders Identification Test (AUDIT) scoreTime frame: Baseline, up to 3 Year Follow-up
  15. Mean Change in PROMIS Cognitive Functioning ScoreTime frame: Baseline, up to 3 Year Follow-up
  16. Mean Change in WAIS-IV Coding and Symbol SearchTime frame: Baseline, up to 3 Year Follow-up
  17. Mean Change in Neuro-Quality Of Life (QOL): Emotional and Behavioral DyscontrolTime frame: Baseline, up to 3 Year Follow-up
  18. Mean Change in Frontal systems behavior scale (FrsBe)Time frame: Baseline, up to 3 Year Follow-up
  19. Mean Change in Everyday Cognition assessment (ECog)Time frame: Baseline, up to 3 Year Follow-up
  20. Mean Change in Minnesota Multiphasic Personality Inventory (MMPI)-2-RF Cognitive Complaints ScaleTime frame: Baseline, up to 3 Year Follow-up
  21. Mean Change in PROMIS_29 ScoreTime frame: Baseline, up to 3 Year Follow-up
  22. Mean Change in Beck Depression Inventory (BDI-II) ScoreTime frame: Baseline, up to 3 Year Follow-up
  23. Mean Change in Beck Anxiety Inventory (BAI-II)-ScoreTime frame: Baseline, up to 3 Year Follow-up
  24. Mean Change in Neuropsychiatric Inventory Questionnaire NPI-Q2 ScoreTime frame: Baseline, up to 3 Year Follow-up
  25. Mean Change in Social Readjustment Rating Scale (SRRS) ScoreTime frame: Baseline, up to 3 Year Follow-up
  26. Mean Change in Ego Resilience Scale (ER89) ScoreTime frame: Baseline, up to 3 Year Follow-up
  27. Mean Change in Athlete Identity Questionnaire ScoreTime frame: Baseline, up to 3 Year Follow-up
  28. Mean Change in Childhood Development and Adversity Questions ScoreTime frame: Baseline, up to 3 Year Follow-up
  29. Mean Change in International Physical Activity Questionnaire (IPAQ) ScoreTime frame: Baseline, up to 3 Year Follow-up
  30. Mean Change in Rapid Eating Assessment for Participants (REAPS) ScoreTime frame: Baseline, up to 3 Year Follow-up

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Boston Children's Hospital

    Waltham, Massachusetts

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.